pharma Neutral 5

Legend Biotech Reports Robust 2025 Growth Driven by Carvykti Scaling

· 3 min read · Verified by 2 sources · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti.
  • The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.

Mentioned

Legend Biotech company LEGN Johnson & Johnson company Carvykti product Core Molding Technologies company CMT

Key Intelligence

Key Facts

  1. 1Carvykti net trade sales saw significant year-over-year growth in 2025 following earlier-line approvals.
  2. 2Manufacturing capacity is on track to reach a target of 10,000 doses annually by year-end 2025.
  3. 3The company maintains a strong cash position with a runway extending into 2027.
  4. 4Legend Biotech and Janssen share profits 50/50 for Carvykti sales outside of Greater China.
  5. 5Pipeline expansion includes LB2102 for small cell lung cancer and other solid tumor candidates.
Market Outlook for LEGN

Analysis

Legend Biotech’s fourth-quarter and full-year 2025 results mark a pivotal transition from a clinical-stage innovator to a commercial powerhouse in the cell therapy space. The primary driver of this growth remains Carvykti (ciltacabtagene autoleucel), the BCMA-directed CAR-T therapy co-developed with Johnson & Johnson’s Janssen unit. Throughout 2025, Legend successfully navigated the manufacturing bottlenecks that had previously constrained the therapy’s market penetration, allowing for a broader rollout in earlier lines of treatment for multiple myeloma. This commercial acceleration is a direct result of the CARTITUDE-4 trial data, which positioned Carvykti as a preferred option for patients who have received at least one prior line of therapy.

Financially, the company has demonstrated a disciplined approach to capital allocation while aggressively investing in its manufacturing infrastructure. The expansion of the Raritan, New Jersey facility and the operationalization of the Obelisc facility in Ghent, Belgium, have been instrumental in meeting the rising global demand. These sites are critical to Legend's strategy of achieving a production capacity of 10,000 doses annually by the end of 2025. By securing its supply chain and increasing throughput, Legend has effectively widened its competitive moat against Bristol Myers Squibb’s Abecma, which has faced its own set of regulatory and commercial hurdles in the BCMA category.

The primary driver of this growth remains Carvykti (ciltacabtagene autoleucel), the BCMA-directed CAR-T therapy co-developed with Johnson & Johnson’s Janssen unit.

The 2025 fiscal year also saw Legend Biotech maintain a robust cash position, providing a multi-year runway that mitigates the need for immediate dilutive financing. This capital is being deployed not only to support Carvykti’s commercial lifecycle but also to advance a diversifying pipeline. Investors are particularly focused on LB2102, the company’s autologous CAR-T candidate for small cell lung cancer (SCLC), which represents Legend’s first major foray into solid tumors. Early-stage data from this program suggests that the company’s expertise in hematological malignancies may be successfully translated to more complex oncological indications.

What to Watch

Looking ahead, the market will be watching for the continued expansion of Carvykti into international markets, particularly in Europe and Asia, where regulatory approvals have paved the way for 2026 growth. The partnership with Johnson & Johnson remains a cornerstone of Legend’s strategy, providing the commercial scale and regulatory expertise necessary to dominate the multiple myeloma landscape. As the company moves into 2026, the focus will shift toward optimizing the cost of goods sold (COGS) and achieving a sustainable path to profitability, a milestone that appears increasingly within reach given the current trajectory of Carvykti’s adoption.

In the broader context of the biotech sector, Legend Biotech’s success serves as a blueprint for international collaboration and the commercialization of complex biologics. The company’s ability to scale a personalized therapy—a feat that has eluded many of its peers—highlights the maturity of its operational framework. While the cell therapy market remains competitive, Legend’s 2025 performance reinforces its status as a top-tier player capable of delivering both clinical innovation and commercial results.

Timeline

Timeline

  1. FY 2025 Earnings

  2. Manufacturing Expansion

  3. Pipeline Update

Related Stories

pharma

Eli Lilly Stock Up 25% YTD: Biotech Breakthroughs Drive Growth

Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine.

pharma

GSK's Q1 Sales Grow 15%, Boosting Pharma Pipeline

GSK's strong Q1 performance signals growth in biotech innovation, with sales up and full-year guidance intact, potentially accelerating clinical trials and FDA approvals. This development underscores opportunities in gene therapy and vaccines for biotech firms. Investors in the sector should watch for ripple effects on R&D investments.

pharma

PTFE Membrane and CDMO Markets Surge Amid Biologics Expansion

The global pharmaceutical landscape is seeing a synchronized rise in the PTFE membrane and CDMO sectors as bioprocessing demands higher filtration standards. This growth is fueled by the industry's shift toward complex biologics and the widespread adoption of single-use manufacturing technologies.

pharma

Shanghai Electric Delivers First Large-Scale Biomethanol for Global Shipping

Shanghai Electric has successfully completed the first large-scale biomethanol bunkering for international shipping, sourced from its landmark Taonan project. This milestone marks a significant leap in maritime decarbonization, providing a commercially viable, bio-based alternative to traditional heavy fuel oils.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.